Top

Published in:

01-12-2010 | Review

⁶⁸Ga-Labeled Radiopharmaceuticals for Positron Emission Tomography

Authors: Dinesh Shetty, Yun-Sang Lee, Jae Min Jeong

Published in: Nuclear Medicine and Molecular Imaging | Issue 4/2010

Abstract

⁶⁸Ga is a promising emerging radionuclide for positron emission tomography (PET). It is produced using a ⁶⁸Ge/⁶⁸Ga-generator, and thus, would enable the cyclotron-independent distribution of PET. However, new ⁶⁸Ga-labeled radiopharmaceuticals that can replace ¹⁸F-labeled agents like [¹⁸F]fluorodeoxyglucose (FDG) are needed. Most of the ⁶⁸Ga-labeled derivatives currently used are peptide agents, but the developments of other agents, such as amino acid derivatives, nitroimidazole derivatives, and glycosylated human serum albumin, are being actively pursued in many laboratories. Thus, appearance of new ⁶⁸Ga-labeled radiopharmaceuticals with high impact are expected in the near future. Here, we present an overview of ⁶⁸Ga-labeled agents in terms of their clinical significances and relevances to the management of certain tumors, and pertinent pre-clinical developments.

Breeman WA, Verbruggen AM. The ⁶⁸Ge/⁶⁸Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine? Eur J Nucl Med Mol Imaging. 2007;34:978–81.CrossRefPubMed

Ehrhardt GJ, Welch MJ. A new germanium-63/gallium-68 generator. J Nucl Med. 1978;19:925–9.PubMed

Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced ⁶⁸Ga for medical application. J Nucl Med. 2007;48:1741–8.CrossRefPubMed

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982–93.CrossRefPubMed

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al. Comparison of ⁶⁸Ga-DOTATOC PET and ¹¹¹In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–26.CrossRefPubMed

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. ⁶⁸Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.CrossRefPubMed

Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between ⁶⁸Ga-DOTA-NOC and ¹⁸F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431–8.CrossRefPubMed

Parker D. Tumour targeting with radiolabelled macrocycle–antibody conjugates. Chem Soc Rev. 1990;19:271–91.CrossRef

Harris WR, Pecoraro VL. Thermodynamic binding constants for gallium transferrin. Biochemistry. 1983;22:292–9.CrossRefPubMed

10.

Chong HS, Ma X, Le T, Kwamena B, Milenic DE, Brady ED, et al. Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy. J Med Chem. 2008;51:118–25.CrossRefPubMed

11.

Chong HS, Song HA, Ma X, Milenic DE, Brady ED, Lim S, et al. Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI. Bioconjug Chem. 2008;19:1439–47.CrossRefPubMed

12.

Hoffend J, Mier W, Schuhmacher J, Schmidt K, Dimitrakopoulou-Strauss A, Strauss LG, et al. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl Med Biol. 2005;32:287–92.CrossRefPubMed

13.

Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon GJ, et al. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid and feasibility studies in mice. J Nucl Med. 2008;49:830–6.CrossRefPubMed

14.

Sabatino G, Chinol M, Paganelli G, Papi S, Chelli M, Leone G, et al. A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. J Med Chem. 2003;46:3170–3.CrossRefPubMed

15.

Tanaka K, Masuyama T, Hasegawa K, Tahara T, Mizuma H, Wada Y, et al. A submicrogram-scale protocol for biomolecule-based pet imaging by rapid 6p-azaelectrocyclization: visualization of sialic acid dependent circulatory residence of glycoproteins. Angew Chem Int Ed. 2008;47:102–5.CrossRef

16.

Tsang BW, Mathias CJ, Fanwick PE, Green MA. Structure-distribution relationships for metal-labeled myocardial imaging agents: comparison of a series of cationic gallium (III) complexes with hexadentate bis(salicylaldimine) ligands. J Med Chem. 1994;37:4400–6.CrossRefPubMed

17.

Tsang BW, Mathias CJ, Green MA. A gallium-68 radiopharmaceutical that is retained in myocardium: 68Ga[(4, 6-MeO2sal)2BAPEN]+. J Nucl Med. 1993;34:1127–31.PubMed

18.

Kung HF, Liu BL, Mankoff D, Kung MP, Billings JJ, Francesconi L, et al. A new myocardial imaging agent: synthesis, characterization, and biodistribution of gallium-68-BAT-TECH. J Nucl Med. 1990;31:1635–40.PubMed

19.

Fichna J, Janecka A. Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconjug Chem. 2003;14:3–17.CrossRefPubMed

20.

Janoki G, Harwig J, Chanachai W, Wolf W. 67Ga desferrioxamine–HSA: synthesis of chelon protein conjugates using carbodiimide as a coupling agent. Int J Appl Radiat Isot. 1983;34:871–7.CrossRefPubMed

21.

Koizumi M, Endo K, Kunimatsu M, Sakahara H, Nakashima T, Kawamura Y, et al. Preparation of ⁶⁷Ga-labeled antibodies using deferoxamine as a bifunctional chelate. An improved method. J Immunol Methods. 1987;104:93–102.CrossRefPubMed

22.

Mathias CJ, Sun YZ, Welch MJ, Connett JM, Philpott GW, Martell AE. N,N'-bis(2-hydroxybenzyl)-1-(4-bromoacetamidobenzyl)-1,2-ethylenediamine-N,N'-diacetic acid: a new bifunctional chelate for radiolabeling antibodies. Bioconjug Chem. 1990;1:204–11.CrossRefPubMed

23.

Broan C, Cox J, Craig A, Kataky R, Parker D, Harrison A, et al. Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: kinetically stable complexes for use in imaging and radioimmunotherapy. X-ray molecular structure of the indium and gallium complexes of 1,4,7-triazacyclononane-1,4,7-triacetic acid. J Chem Soc Perkin Trans. 1991;2:87–99.

24.

Liu S, Edwards DS. Synthesis and characterization of two ¹¹¹In-labeled DTPA-peptide conjugates. Bioconjug Chem. 2001;12:630–4.CrossRefPubMed

25.

Chong HS, Garmestani K, Ma D, Milenic DE, Overstreet T, Brechbiel MW. Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics. J Med Chem. 2002;45:3458–64.CrossRefPubMed

26.

Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med. 1997;70:471–9.PubMed

27.

Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med. 1997;41:63–70.PubMed

28.

Schonbrunn A. Somatostatin receptors present knowledge and future directions. Ann Oncol. 1999;10:S17–21.CrossRefPubMed

29.

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.CrossRefPubMed

30.

Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP. Comparison of ^111In-DOTA-Tyr3-octreotide and ¹¹¹In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med. 1999;40:762–7.PubMed

31.

Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–47.CrossRefPubMed

32.

Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R, et al. Gallium-67/gallium-68-[DFO]-octreotide—a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med. 1994;35:317–25.PubMed

33.

Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med. 2001;28:1421–9.CrossRefPubMed

34.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46 Suppl 1:62S–6S.PubMed

35.

Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. ⁶⁸Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.CrossRefPubMed

36.

Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–47.CrossRefPubMed

37.

Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Vavere AL, et al. Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol. 2007;34:945–53.CrossRefPubMed

38.

Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, et al. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004;45:116–23.PubMed

39.

van Hagen PM, Breeman WA, Reubi JC, Postema PT, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med. 1996;23:1508–13.CrossRefPubMed

40.

de Visser M, Janssen PJ, Srinivasan A, Reubi JC, Waser B, Erion JL, et al. Stabilised ¹¹¹In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2003;30:1134–9.CrossRefPubMed

41.

Behr TM, Behe MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med. 2002;32:97–109.CrossRefPubMed

42.

Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand ¹²⁵I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res. 2002;8:1139–46.PubMed

43.

Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007;34:1198–208.CrossRefPubMed

44.

Lankinen P, Makinen TJ, Poyhonen TA, Virsu P, Salomaki S, Hakanen AJ, et al. ⁶⁸Ga-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones. Eur J Nucl Med Mol Imaging. 2008;35:352–64.CrossRefPubMed

45.

Makinen TJ, Lankinen P, Poyhonen T, Jalava J, Aro HT, Roivainen A. Comparison of ¹⁸F-FDG and ⁶⁸Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus. Eur J Nucl Med Mol Imaging. 2005;32:1259–68.CrossRefPubMed

46.

Roivainen A, Tolvanen T, Salomaki S, Lendvai G, Velikyan I, Numminen P, et al. ⁶⁸Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med. 2004;45:347–55.PubMed

47.

Clarke ET, Martell AE. Stabilities of the Fe(Iii), Ga(Iii) and in(Iii) chelates of N,N',N''-triazacyclononanetriacetic acid. Inorg Chim Acta. 1991;181:273–80.CrossRef

48.

Clarke ET, Martell AE. Potentiometric and spectrophotometric determination of the stabilities of in(Iii), Ga(Iii) and Fe(Iii) complexes of N,N',N''-tris(3,5-dimethyl-2-hydroxybenzyl)-1,4,7-triazacyclononane. Inorg Chim Acta. 1991;186:103–11.CrossRef

49.

Clarke ET, Martell AE. Stabilities of trivalent metal-ion complexes of the tetraacetate derivatives of 12-membered, 13-membered and 14-membered tetraazamacrocycles. Inorg Chim Acta. 1991;190:37–46.CrossRef

50.

Shetty D, Jeong JM, Hoigebazar L, Lee YS, Lee DS, Chung JK, et al. (2010) Formation and characterization of gallium(III) complexes with monoamide derivatives of 1,4,7-triazacyclononane-1,4,7-triacetic acid: a pH dependant structural study. Eur J Inorg Chem 2010:In press.

51.

Shetty D, Ju CH, Kim YJ, Lee JY, Lee YS, Lee DS, et al. (2010) Synthesis and evaluation of macrocyclic amino acid derivatives for tumor imaging by gallium-68 positron emission tomography. Bioorg Med Chem 18. doi:10.1016/j.bmc.2010.09.022

52.

Shetty D, Ju CH, Lee YS, Jeong SY, Choi JY, Yang BY, et al. (2010) Synthesis of novel ⁶⁸Ga labeled amino acid derivatives for positron emission tomography of cancer cells. Nucl Med Biol 37. doi:10.1016/j.nucmedbio.2010.06.003

53.

Ito M, Yang DJ, Mawlawi O, Mendez R, Oh CS, Azhdarinia A, et al. PET and planar imaging of tumor hypoxia with labeled metronidazole. Acad Radiol. 2006;13:598–609.CrossRefPubMed

54.

Hoigebazar L, Jeong JM, Choi SY, Choi JY, Shetty D, Lee YS, et al. Synthesis and characterization of nitroimidazole derivatives for 68Ga-labeling and testing in tumor xenografted mice. J Med Chem. 2010;53:6378–85.CrossRefPubMed

55.

Sharma V, Prior JL, Belinsky MG, Kruh GD, Piwnica-Worms D. Characterization of a ⁶⁷Ga/⁶⁸Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med. 2005;46:354–64.PubMed

56.

Choi JY, Yoo BC, Kim K, Kim Y, Yang BY, Lee YS, et al. (2010) Development of ⁶⁸Ga-labeled mannosylated human serum albumin (MSA) as a lymph node imaging agent for positron emission tomography. Nucl Med Biol 37. doi:10.1016/j.nucmedbio.2010.09.010

57.

Yang BY, Jeong JM, Kim YJ, Choi JY, Lee YS, Lee DS, et al. Formulation of ⁶⁸Ga BAPEN kit for myocardial positron emission tomography imaging and biodistribution study. Nucl Med Biol. 2009;37:149–55.CrossRefPubMed

58.

Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand ⁶⁸Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751–7.CrossRefPubMed

59.

Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, et al. Evaluation of the pharmacokinetics of ⁶⁸Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for ⁹⁰Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:460–6.CrossRefPubMed

60.

Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [⁶⁸Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [¹¹¹In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42–8.CrossRefPubMed

61.

Win Z, Al-Nahhas A, Towey D, Todd JF, Rubello D, Lewington V, et al. ⁶⁸Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun. 2007;28:359–63.CrossRefPubMed

62.

Win Z, Rahman L, Murrell J, Todd J, Al-Nahhas A. The possible role of ⁶⁸Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging. 2006;33:506.CrossRefPubMed

63.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of ⁶⁸Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46:763–9.PubMed

Title: 68Ga-Labeled Radiopharmaceuticals for Positron Emission Tomography
Authors: Dinesh Shetty
Yun-Sang Lee
Jae Min Jeong
Publication date: 01-12-2010
Publisher: Springer-Verlag
Published in: Nuclear Medicine and Molecular Imaging / Issue 4/2010
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-010-0056-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

⁶⁸Ga-Labeled Radiopharmaceuticals for Positron Emission Tomography

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Hypermetabolic Axillary Mass on 18F FDG PET/CT: Breast Cancer Arising from Accessory Breast Tissue

Reproducibility of Gallbladder Ejection Fraction Measured by Fatty Meal Cholescintigraphy

Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131

Radiation Safety Issues in Y-90 Microsphere Selective Hepatic Radioembolization Therapy: Possible Radiation Exposure from the Patients

Behavior and Awareness of Thyroid Cancer Patients in Korea Having Non-Hospitalized Low-Dose Radioiodine Treatment with Regard to Radiation Safety

Multiple Skeletal Muscle Metastases in a Case of Transitional Cell Carcinoma of Bladder Detected by F-18 FDG PET/CT